News

10.26.21

Press Release

Achieve Life Sciences to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 9, 2021

Seattle, WA/ Vancouver, BC , Oct. 26, 2021 —  Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it will report its third-quarter 2021 financial results and provide an update on the cytisinicline development program on Tuesday, November 9, 2021,…

/Read More

09.15.21

Press Release

Achieve Life Sciences to Participate in Upcoming Investor Conferences

SEATTLE, Wash and VANCOUVER, British Columbia, September 15, 2021 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that John Bencich, Chief Executive Officer, will participate in two upcoming investor conferences. Mr. Bencich will present at…

/Read More

09.14.21

Press Release

Achieve Life Sciences Announces Presentation of Cytisinicline Data at the 21st Annual Society for Research on Nicotine & Tobacco (SRNT-E) Virtual Conference

SEATTLE, Wash. and VANCOUVER, British Columbia, September 14, 2021 – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that cytisinicline data will be presented at two sessions during the upcoming Society for Research on Nicotine & Tobacco…

/Read More

09.09.21

Press Release

Achieve Life Sciences to Participate in Two Upcoming Investor Conferences

SEATTLE, Wash and VANCOUVER, British Columbia, September 9, 2021 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that John Bencich, Chief Executive Officer, will be participating in two upcoming investor conferences. Mr. Bencich will present…

/Read More

08.13.21

Press Release

Achieve Life Sciences Announces Expansion of Cytisinicline Clinical Operations Team and Granting of Inducement Awards

SEATTLE, Wash. and VANCOUVER, British Columbia, August 13, 2021 — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that the Company has expanded its Clinical Operations Team with the hiring of a Director of Clinical Operations,…

/Read More